Form 4 for IDXX Idexx Laboratories
Accepted 2023-05-05 00:00:00 ET · period of report 2023-05-04 · accession 0000874716-23-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-05-05 | 2023-05-04 | IDXX | Vandebroek Sophie V. | Dir | G - Gift | $0.00 | -500 | 8,173 | -6% | $0 |
| D | 2023-05-05 | 2023-05-04 | IDXX | Vandebroek Sophie V. | Dir | M - OptEx | $206.62 | +2,187 | 3,059 | +251% | +$451.9K |
| D | 2023-05-05 | 2023-05-04 | IDXX | Vandebroek Sophie V. | Dir | S - Sale+OE | $469.02 | -2,187 | 872 | -71% | -$1.03M |
| D | 2023-05-05 | 2023-05-04 | IDXX | Vandebroek Sophie V. | Dir | M - OptEx | — | -2,187 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-04 | G | D | 500 | $0.00 | 8,173 | I | — | — | |
| 2 | Common | Common Stock | 2023-05-04 | M | A | 2,187 | $206.62 | 3,059 | D By Sophie V. Vandebroek Revocable Trust | — | — | |
| 3 | Common | Common Stock | 2023-05-04 | S | D | 2,187 | $469.02 | 872 | D | — | — | (F1) Represents the weighted average price of the shares sold ranging from a low of $469.00 to a high of $469.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2023-05-04 | M | D | 2,187 | — | 0 | D | $206.62 · — to 2028-05-08 | 2,187 Common Stock | (F3) Not applicable. (F2) Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier. |